TCR-Like Antibody Pipeline
Cancer, Autoimmunity, Inflammatory Diseases
Pre-clinicalActive
Key Facts
About Nextera
Nextera is a private, preclinical-stage biotech company based in Oslo, Norway, founded in 2016. It has developed the NextCore platform, a unique pIX phage display technology, to generate highly specific TCR-like antibodies that target peptide-HLA (pHLA) complexes, aiming to unlock intracellular disease antigens for immunotherapy. The company is building a pipeline of lead candidates and operates a partnership-driven business model to develop therapies for complex diseases in oncology and autoimmunity. Leadership combines deep scientific expertise in antibody and TCR engineering with business development and financial experience from the biotech sector.
View full company profile